Patents Examined by Angela C Brown-Pettigrew
  • Patent number: 10821121
    Abstract: A topical formulation for transdermal delivery of sub-acute does of doxycycline hyclate to treat pain and inflammation may include: a base suspension; and doxycycline hyclate. The doxycycline hyclate is mixed with the base suspension in a proportion such that the formulation lacks any antibiotic effect and the concentration of doxycycline hyclate is between 200 and 600 mg/g inclusive. A method of applying the formulation is also disclosed.
    Type: Grant
    Filed: June 28, 2018
    Date of Patent: November 3, 2020
    Inventor: Bruce Roseman
  • Patent number: 10821088
    Abstract: The present invention relates to TRPV1 selective agonist topical compositions including capsaicinoid and analgesic agent compositions and methods of manufacture and methods of providing pain relief as well as treating a variety of disorders with such compositions.
    Type: Grant
    Filed: September 10, 2014
    Date of Patent: November 3, 2020
    Assignee: PROPELLA THERAPEUTICS, INC.
    Inventors: Daniel Bucks, Philip J. Birbara
  • Patent number: 10806735
    Abstract: The invention relates to methods for treating chronic liver disease, in particular nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), with neutrophil elastase inhibitors. The invention further relates to pharmaceutical compositions comprising neutrophil elastase inhibitors.
    Type: Grant
    Filed: April 22, 2019
    Date of Patent: October 20, 2020
    Assignee: pH Pharma Co., Ltd.
    Inventors: Sanjeev Satyal, Brian Roberts, Xueyan Wang, Scott Savage, Hoyoung Huh
  • Patent number: 10806785
    Abstract: Compositions and methods for inducing PD-L1 internalization are disclosed. The methods include reducing the amount of cell surface PD-L1 by contacting a cell expressing PD-L1 with a compound that binds to cell surface PD-L1 and induces PD-L1 internalization. Compounds that induce PD-L1 internalization can be used to enhance, stimulate and/or increase an immune response and treat a PD-1-related disease or condition.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: October 20, 2020
    Assignee: Incyte Corporation
    Inventors: Liang Lu, Wenyu Zhu, Ding-Quan Qian, Kaijiong Xiao
  • Patent number: 10806144
    Abstract: Disclosed herein are compositions comprising benzyl alcohol, one or more cationic antimicrobial agent, and one or more emollient, the combination of which results in persistent antimicrobial activity after application to the skin. The compositions optionally further comprise an organic acid and/or a zinc salt, such as zinc gluconate, as an anti-irritant.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: October 20, 2020
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Shanta M. Modak, Santoshkumar Hanmantrao Dongre
  • Patent number: 10799598
    Abstract: Provided are bispecific conjugates having the general formula: pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and their use in the treatment of cancer.
    Type: Grant
    Filed: August 1, 2018
    Date of Patent: October 13, 2020
    Assignee: Sorrento Therapeutics, Inc.
    Inventors: James T. Patterson, Gunnar F. Kaufmann, Yanwen Fu, Tong Zhu
  • Patent number: 10765643
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the treatment of seizures associated with Aicardi Syndrome. In one embodiment the seizures associated with Aicardi Syndrome are convulsive seizures; focal seizures with impairment or infantile spasm. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Grant
    Filed: October 14, 2015
    Date of Patent: September 8, 2020
    Assignee: GW Research Limited
    Inventors: Geoffrey Guy, Stephen Wright, Orrin Devinsky
  • Patent number: 10758556
    Abstract: The present invention relates to antibody drug conjugates (ADCs) presenting improved properties of in vivo tolerability.
    Type: Grant
    Filed: August 6, 2019
    Date of Patent: September 1, 2020
    Assignee: NBE-THERAPEUTICS AG
    Inventors: Ulf Grawunder, Roger Beerli, Remy Gebleux
  • Patent number: 10744131
    Abstract: Disclosed are abuse resistant oral pharmaceutical compositions that reduce the likelihood of improper administration of drugs that are susceptible to abuse. The oral pharmaceutical formulations contain abuse deterrent agents that cause discomfort to the user when administered in an improper manner and make the extraction of an active ingredient more difficult. Methods of making and using the compositions are also disclosed.
    Type: Grant
    Filed: December 31, 2014
    Date of Patent: August 18, 2020
    Assignee: KASHIV BIOSCIENCES, LLC
    Inventors: Harpreet Kaur Sandhu, Siva Ram Kiran Vaka, Ashish Chatterji, Dipen Desai, Wantanee Phuapradit, Navnit H. Shah
  • Patent number: 10722513
    Abstract: The present invention relates to compositions, methods and kits for the treatment of respiratory disease. In particular, the compositions, methods and kits are particularly useful, but not limited to, the treatment or prevention of exacerbations of asthma and chronic obstructive pulmonary disease. The present invention provides a method of treating or preventing a respiratory disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an inhibitor of casein kinase 1, thereby treating or preventing a respiratory disease in a subject. The present invention also provides a method of treating or preventing a respiratory disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an inhibitor of ALK5, thereby treating or preventing a respiratory disease in a subject, wherein the inhibitor is administered directly to the airway and/or lungs.
    Type: Grant
    Filed: March 23, 2016
    Date of Patent: July 28, 2020
    Assignee: THE UNIVERSITY OF MELBOURNE
    Inventors: Alastair Stewart, Christine Keenan, Trudi Harris
  • Patent number: 10710987
    Abstract: Provided herein are novel solid forms of N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl (tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4?-(morpholinomethyl)-[1,1?-biphenyl]-3-carboxamide hydrochloride, and related compositions and methods.
    Type: Grant
    Filed: June 5, 2018
    Date of Patent: July 14, 2020
    Assignees: Epizyme, Inc., Eisai R&D Management Co., Ltd.
    Inventors: Kevin Wayne Kuntz, Hyeong Wook Choi, Steven Mathieu, Kristen Sanders, Arani Chanda
  • Patent number: 10688179
    Abstract: Disclosed is a single unit oral dosage form having, in combination, inositol and an extended release clonidine or extended release guanfacine. In one aspect, a method for treating ADHD and/or associated symptoms thereof includes administering to an ADHD patient the single unit oral dosage form. In another aspect, a method for treating ADHD and/or associated symptoms thereof includes administering to an ADHD patient inositol in combination with extended release clonidine or extended release guanfacine, whether administered separately or as a single dosage form.
    Type: Grant
    Filed: August 1, 2019
    Date of Patent: June 23, 2020
    Inventor: Richard Louis Price
  • Patent number: 10668084
    Abstract: The present invention relates to lower dosage strength pernasal testosterone gel formulations for intranasal administration and treatment methods for using the lower dosage strength pernasal testosterone gel formulations for treating a female subject with anorgasmia and/or hypoactive sexual desire disorder.
    Type: Grant
    Filed: October 20, 2015
    Date of Patent: June 2, 2020
    Assignee: Acerus Biopharma Inc.
    Inventors: Wayne Kreppner, Siobhan Fogarty, Werner Oberegger, Paul José Pierre Marie Maes
  • Patent number: 10669285
    Abstract: Compounds of formula (I) wherein R1, R2, A1 and A2 are as described herein, compositions including the compounds and methods of using the compounds as autotaxin inhibitors.
    Type: Grant
    Filed: September 21, 2016
    Date of Patent: June 2, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Daniel Hunziker, Jerome Hert, Holger Kuehne, Patrizio Mattei, Markus Rudolph
  • Patent number: 10653691
    Abstract: A method of promoting remyelination in a subject in need thereof includes administering to the subject a therapeutically effective amount of at least one (1,3) Diazole compound, wherein the therapeutically effective amount is the amount effective to induce endogenous oligodendrocyte precursor cell (OPC) differentiation in the subject's central nervous system.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: May 19, 2020
    Assignee: Case Western Reserve University
    Inventors: Paul J. Tesar, Fadi J. Najm, Robert H. Miller
  • Patent number: 10646461
    Abstract: A pharmacological composition for the treatment of bacterial and protozoal infections in a patient. The preferred pharmacological composition comprises a pharmaceutical carrier and an active composition selected from the group consisting of: a) an amount of sodium oxalate and an amount of oxalic acid, b) an amount of sodium citrate and an amount of citric acid, or c) mixtures of a) and b). The amounts and weight ratios of a) the sodium oxalate and oxalic acid, and b) the sodium citrate and citric acid in the active composition are such as to produce a safe and effective pharmacological composition. Sodium salts of other carboxylic acids may be used. The invention also relates to the method of using the pharmacological composition for the safe and effective treatment of bacterial infections, protozoal infections and dermatological diseases.
    Type: Grant
    Filed: November 19, 2019
    Date of Patent: May 12, 2020
    Inventor: Naeem Uddin
  • Patent number: 10632121
    Abstract: In certain embodiments the present invention involves methods of killing tumor cells that comprise an oncogenic PDGFR mutation, and methods of treating subjects having tumors that comprise such tumor cells. In some embodiments such methods involve using PI3K inhibitors, or a combination of a PI3K inhibitor and an mTOR inhibitor, or a dual PI3K/mTOR inhibitor. The present invention also provides methods for determining whether a subject is a candidate for treatment, methods for evaluating the efficacy of treatment, and other methods, compositions, model systems, and assays.
    Type: Grant
    Filed: May 15, 2015
    Date of Patent: April 28, 2020
    Inventors: Ingo Kai Mellinghoff, Sara Kubek
  • Patent number: 10624876
    Abstract: The present invention relates to compounds of formula (I) and pharmaceutical compositions comprising such compounds, for use for treating and/or preventing endometriosis.
    Type: Grant
    Filed: October 23, 2017
    Date of Patent: April 21, 2020
    Assignee: BIOKINESIS
    Inventor: Philippe Pouletty
  • Patent number: 10610514
    Abstract: The present invention relates to a composition including an inhibitor against the function of an Mi-2/NuRD chromatin remodeling complex for inhibiting metastasis and preventing and treating cancer diseases, and more particularly, the composition may inhibit the MBD2-p66? (GATAD2A) interaction by means of the Mi-2/NuRD CRC function inhibitor, and thus is expected to be effectively used as a composition capable of inhibiting metastasis and preventing and treating cancer diseases.
    Type: Grant
    Filed: November 24, 2017
    Date of Patent: April 7, 2020
    Assignees: Industry-University Cooperation Foundation Hanyang University, University of South Florida
    Inventors: Chul Geun Kim, Min Young Kim, Young Su Lim, Dae Hyun Ha, Young Yiul Lee, Buom Yong Ryu, Vladimir Uversky, Insung Na, Yu Chen, Arjan van der Vaart
  • Patent number: 10590063
    Abstract: Compositions and methods for inhibiting, treating, and/or preventing fatty acid metabolism disorders, particularly fatty acid oxidation disorders, in a subject are provided.
    Type: Grant
    Filed: November 7, 2016
    Date of Patent: March 17, 2020
    Assignee: THE CHILDREN'S HOSPITAL OF PHILADELPHIA
    Inventors: Harry Ischiropoulos, Paschalis-Thomas Doulias